- Postoperative Nausea and Vomiting (PONV) treatments, which include a range of antiemetic drugs and supportive therapies, are increasingly vital components of enhanced recovery after surgery (ERAS) protocols in both hospital and ambulatory settings due to their ability to improve patient comfort, reduce complications, and shorten recovery time
- The escalating demand for PONV treatments is primarily fueled by the rising number of surgical procedures worldwide, growing awareness of patient-centric care, and the increasing adoption of combination therapies to manage nausea and vomiting more effectively
- North America dominated the postoperative nausea and vomiting treatment market with the largest revenue share of 39.8% in 2024, characterized by the early implementation of ERAS programs, high healthcare expenditure, and a strong presence of pharmaceutical manufacturers
- Asia-Pacific is expected to be the fastest-growing region in the postoperative nausea and vomiting treatment market during the forecast period due to increasing surgical volumes, rising healthcare investments, and growing awareness about post-surgical care across countries such as China, India, and Japan
- Postoperative Nausea and Vomiting (PONV) segment dominated the postoperative nausea and vomiting treatment market with a market share of 45.2% in 2024, owing to the increasing number of surgical procedures and the widespread implementation of Enhanced Recovery After Surgery (ERAS) protocols that emphasize effective nausea and vomiting management to improve patient outcomes and reduce recovery time
